Bardoxolone methyl , an Nrf@-activating and nuclear factor-B-inhibiting semisynthetic oleanane triterpenoid compound , was evaluated in a phase @ trial ( BEACON ) in patients with type @ diabetes mellitus ( T@DM ) and stage @ chronic kidney disease ( CKD ) .